Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000282876 | SCV000342867 | uncertain significance | not provided | 2016-06-09 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000282876 | SCV001144074 | uncertain significance | not provided | 2019-05-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002521996 | SCV003440924 | likely pathogenic | GNE myopathy; Sialuria | 2022-01-05 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GNE protein function. ClinVar contains an entry for this variant (Variation ID: 288683). This variant is also known as c.1721T>C (Ile557Thr). This missense change has been observed in individuals with distal myopathy (PMID: 12497639, 15136692). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 588 of the GNE protein (p.Ile588Thr). |
Natera, |
RCV001828255 | SCV002075634 | uncertain significance | GNE myopathy | 2021-01-27 | no assertion criteria provided | clinical testing |